Zymeworks (ZYME) EVP holds 167,000 options and 111,111 RSUs
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Zymeworks Inc. executive Platshon Scott, EVP and Chief Business Officer, reported initial equity awards in a Form 3. The filing lists stock options covering 167,000 shares of common stock at an exercise price of $22.99 per share, expiring November 17, 2035, plus 111,111 restricted stock units. The options vest 25% on the first anniversary of the November 18, 2025 grant and the remainder in 36 equal monthly installments, while the RSUs vest in three equal annual installments beginning November 18, 2026, with each RSU representing the right to receive one share of common stock upon vesting.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Platshon Scott
Role
EVP, Chief Business Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | No securities are beneficially owned | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 167,000 shares (Direct);
Restricted Stock Unit — 111,111 shares (Direct);
No securities are beneficially owned — 0 shares (Direct)
Footnotes (1)
- Stock option granted November 18, 2025. Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Restricted stock units ("RSUs") granted November 18, 2025; vest in three equal annual installments beginning November 18, 2026. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
Key Figures
Stock options underlying shares: 167,000 shares
Option exercise price: $22.99 per share
Restricted stock units: 111,111 RSUs
+3 more
6 metrics
Stock options underlying shares
167,000 shares
Right to buy common stock at $22.99; expire November 17, 2035
Option exercise price
$22.99 per share
Exercise price for 167,000 stock options granted November 18, 2025
Restricted stock units
111,111 RSUs
Granted November 18, 2025; vest in three equal annual installments
Option vesting schedule
25% then 36 monthly installments
25% on first anniversary of November 18, 2025; remainder in 36 monthly tranches
RSU vesting start date
November 18, 2026
RSUs vest in three equal annual installments beginning on this date
Option expiration date
November 17, 2035
Expiration date for the 167,000-share stock option grant
Key Terms
Stock Option (Right to Buy), Restricted stock units ("RSUs"), vesting, exercise price, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with exercise price $22.99"
Restricted stock units ("RSUs") financial
"Restricted stock units ("RSUs") granted November 18, 2025; vest in three equal annual installments"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting financial
"Stock options vest as follows: (i) 25% ... and (ii) remainder ... in 36 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"exercisePrice: "22.9900" for Stock Option (Right to Buy) over common stock"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
beneficially owned financial
"security_title: "No securities are beneficially owned" in one holding entry"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
FAQ
What insider holdings did Zymeworks (ZYME) report for EVP Platshon Scott on the Form 3?
Zymeworks reported that EVP and Chief Business Officer Platshon Scott holds stock options over 167,000 common shares at $22.99 and 111,111 restricted stock units. These awards reflect his initial reported equity position with the company in options and RSUs rather than open-market share purchases.
What are the terms of Platshon Scott’s Zymeworks stock options reported on the Form 3?
The stock options give Platshon Scott the right to buy 167,000 Zymeworks common shares at $22.99 per share, expiring November 17, 2035. They vest 25% on the first anniversary of the November 18, 2025 grant, with the remaining options vesting in 36 equal monthly installments.
How do Platshon Scott’s Zymeworks restricted stock units (RSUs) vest?
Platshon Scott’s 111,111 restricted stock units were granted November 18, 2025 and vest in three equal annual installments starting November 18, 2026. Each RSU represents a contingent right to receive one share of Zymeworks common stock upon vesting, aligning compensation with future service.
What is the exercise price and expiration date of Zymeworks options held by Platshon Scott?
The reported stock options held by Platshon Scott have an exercise price of $22.99 per share and expire on November 17, 2035. These options relate to underlying Zymeworks common stock and follow a multi-year vesting schedule beginning one year after the November 18, 2025 grant date.